Skip to main content
. 2015 Aug 26;10(8):e0136328. doi: 10.1371/journal.pone.0136328

Table 1. Characterization of mAb activities against DENV4 by ELISA, IFA, WB, and PRNT50.

mAbs Isotyping Class a ELISA b IFA c WB d Specificity e DENV4 PRNT50 (μg/ml) f
D1 D2 D3 D4 D1 D2 D3 D4 D1 D2 D3 D4
DD1-4 IgG2a, κ Type - - - + - - - + - - - + EDI-II >40
DD3-7 IgG1, κ Type - - - + - - - + - - - + NS1 n.d.
DD4-3 IgG2a, κ Type - - - + - - - + - - - + E >40
DD5-1 IgG1, κ Type - - - + - - - + - - - + E >40
DD7-8 IgG2a, κ Subcomplex + - - + + - - + + - - + NS1 n.d.
DD9-4 IgG2a, κ Type - - - + - - - + - - - + E >40
DD11-4 IgG1, κ Complex + + + + + + + + + + + + EDI-II >40
DD13-4 IgG1, κ Type - - - + - - - + - - - + EDI-II >40
DD14-1 IgG2a, κ Subcomplex - - + + - - + + - - + + EDI-II >40
DD15-2 IgG2b, κ Subcomplex - - + + - - + + - - + + E >40
DD17-4 IgG2a, κ Type - - - + - - - + - - - + EDIII >40
DD18-5 IgG2a, κ Complex + + + + + + + + + + + + EDI-II ≧20
DD27-8 IgG2a, κ Type - - - + - - - + - - - + EDIII >40
DD30-4 IgG2a, κ Type - - - + - - - + - - - + EDI-II >40
DD31-3 IgG1, κ Type - - - + - - - + - - - + EDI-II >40
DD33-2 IgG1, κ Subcomplex - + - + - + - + - + - + NS1 n.d.

a The classes of mAbs include complex-reactive, subcomplex-reactive, and type-specific. The results were determined by ELISA, IFA, and WB.

b Plates coated with rabbit hyper-immune sera against DENV1-4 were used to test the reactivity of mAbs. (+) The OD values above cut off value were positive (+), and those below were negative (-).

c The IFA results using DENV1-4-infected BHK-21 cells were confirmed as described in the Methods.

d Western blotting (WB) using cell lysates from DENV1-4-infected C6/36 cells was performed as described in the Methods.

e The specificities of mAbs were determined using lysates of virus-infected cells. The binding domains of mAbs were identified by recombinant proteins. E: envelope protein; EDI-II, recombinant domain I-II of E protein; EDIII, recombinant domain III of E protein; NS1, nonstructural protein 1.

f The PRNT50 values are shown as the lowest concentration of mAbs that reduced ≧50% of plaques. (n.d.) not determined.